Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society…

By Global News Feed

--Final 12-Month Results from Phase II Trial to be Presented on October 1--LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).

Here is the original post:
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society...

BetterLife Provides Update on OTC Trading Activity

By Global News Feed

VANCOUVER, Sept. 23, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that it has filed a Form 211 application with the Financial Industry Regulatory Authority (“FINRA”) to request permission to quote and resume trading of its securities on OTC Markets.

See the original post here:
BetterLife Provides Update on OTC Trading Activity

Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

By Global News Feed

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020.

Go here to see the original:
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

By Global News Feed

MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.

See original here:
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

By Global News Feed

BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000.

Read the original post:
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development

By Global News Feed

Glen Rock, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment on September 15, 2020, of David Dickason as Senior Vice President Pre-clinical Product Development.

See the rest here:
RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development

Medcolcanna Organics Announces Final Approval for Listing of Common Shares on the NEO Exchange

By Global News Feed

BOGOTÁ, Colombia, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medcolcanna Organics Inc. (“Medcolcanna”, “MCCN” or the “Company”) (TSXV: MCCN), a Canadian integrated medical cannabis company with operations in Colombia, is pleased to announce that it has received final approval to have the common shares of the Company (“Common Shares”) listed on Neo Exchange Inc. (the “NEO Exchange”). Consequently, the Company has also submitted a request to the TSX Venture Exchange (the “TSXV”) to voluntarily delist the Common Shares from the TSXV. The Company anticipates the delisting of the Common Shares from the TSXV and the subsequent listing of the Common Shares on the NEO Exchange to occur on or about the week of October 12th, 2020, subject to satisfaction of customary conditions by the NEO Exchange and the TSXV. Company Management is excited with the prospect of listing the Common Shares on the NEO Exchange and the opportunities it provides to its investors, as the Company continues the ongoing development of its business operations, including pursuing operations in the United States as integral to its business and the value that it expects to provide to its shareholders. The Company will provide further updates in future press releases surrounding the status and timing of the transfer of the listing of its Common Shares.

More here:
Medcolcanna Organics Announces Final Approval for Listing of Common Shares on the NEO Exchange

→←